구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine) Byondis B.V.·Metastatic Breast Cancer 23 trials |
|---|---|
Overview Program | (vic-)trastuzumab duocarmazine |
Overview Company | Byondis B.V. |
Overview Modality | ADC |
Overview Target | Metastatic Breast Cancer |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.. Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degrada… |
Toxicology CRS | Reported |
Clinical Safety signal | The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.. Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degrada… |
Clinical Selected reported efficacy | ORR 27.8% |
Clinical Reported ORR | 27.8% |
Clinical Reported PFS | 7.0 |
Clinical Reported OS | 21.0 |
Clinical Result source | ClinicalTrials.gov NCT03262935 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03262935 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine) Byondis B.V.·Metastatic Breast Cancer 23 trials |
|---|---|
Overview Program | (vic-)trastuzumab duocarmazine |
Overview Company | Byondis B.V. |
Overview Modality | ADC |
Overview Target | Metastatic Breast Cancer |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.. Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degrada… |
Toxicology CRS | Reported |
Clinical Safety signal | The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.. Transitioning a candidate therapeutic target from bench to bedside requires significant time and financial investment, yet clinical success remains low often due to poor on-target toxicity assessment during preclinical validation. Tag-degraders provide a tool to improve target validation by enabling degrada… |
Clinical Selected reported efficacy | ORR 27.8% |
Clinical Reported ORR | 27.8% |
Clinical Reported PFS | 7.0 |
Clinical Reported OS | 21.0 |
Clinical Result source | ClinicalTrials.gov NCT03262935 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03262935 |
추천 비교
추천 비교